BEUDAMED
    FDA PMA FDA Class 3 Approved 🇺🇸 United States

    Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer

    PMA: P950021 · Supplement: S007 · Decision Oct 7, 2005
    View on FDA
    Classifications
    1
    FEI Numbers
    15
    Registration Numbers
    15

    Basic Information

    Device Name
    Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer
    Trade Name
    ADVIA CENTAUR CP PSA ASSAY
    PMA Number
    P950021
    Supplement Number
    S007
    Device Class
    FDA Class 3
    Product Code
    MTF
    Generic Name
    Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer
    Medical Specialty
    Unknown
    Advisory Committee
    Immunology
    Decision
    Approved
    Decision Code
    APPR
    Decision Date
    October 7, 2005
    Date Received
    July 22, 2005
    Supplement Type
    Real-Time Process
    Supplement Reason
    Change Design/Components/Specifications/Material
    Expedited Review
    N

    Advisory Committee Statement

    APPROVAL FOR TRANSFER OF THE ASSAY TO A NEW BAYER PLATFORM, THE ADVIA CENTAUR CP SYSTEM. THE ADVIA CENTAUR CP PSA ASSAY IS INTENDED TO QUANTITATIVELY MEASURE PROSTATE-SPECIFIC-ANTIGEN (PSA) IN HUMAN SERUM USING THE ADVIA CENTAUR CP SYSTEM.

    Classifications

    This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

    Product Code Device Name
    MTF Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer